Skip to main content
Top
Published in: Endocrine 1/2017

01-07-2017 | Original Article

Matrix metalloproteinase 2 (MMP-2) levels are increased in active acromegaly patients

Authors: Alper Cagri Karci, Zeynep Canturk, Ilhan Tarkun, Berrin Cetinarslan

Published in: Endocrine | Issue 1/2017

Login to get access

Abstract

Purpose

During follow-up of acromegaly patients, there is a discordance rate of 30% between the measurements of growth hormone and insulin-like growth factor-1 levels. Further tests are required to determine disease activity in patients with discordant results. This study was planned to investigate an association of serum levels of matrix metalloproteinase-2, matrix metalloproteinase-9, and cathepsin B with disease activity in acromegaly patients.

Methods

In this study, 64 acromegaly patients followed in our clinic were divided into two groups according to the 2010 consensus criteria for cure of acromegaly as patients with active disease (n = 24) and patients with controlled disease (n = 40). Serum matrix metalloproteinase-2, matrix metalloproteinase-9, and cathepsin B levels were measured by the enzyme-linked immunosorbent assay method.

Results

The mean serum matrix metalloproteinase-2 level was significantly higher in the active acromegaly patients than in the controlled acromegaly patients (150.1 ± 54.5 ng/mL vs. 100.2 ± 44.6 ng/mL; p < 0.0001). There was no significant difference between the active and controlled acromegaly patients regarding serum matrix metalloproteinase-9 and cathepsin B levels (p = 0.205 and p = 0.598, respectively). Serum matrix metalloproteinase-2 levels of 118.3 ng/mL and higher had a sensitivity of 75% and a specificity of 77.5% in determining active disease. The risk of active acromegaly was 3.3 fold higher in the patients with a matrix metalloproteinase-2 level of >118.3 ng/mL than in the patients with a matrix metalloproteinase-2 level of <118.3 ng/mL.

Conclusions

In this study, serum matrix metalloproteinase-2 level is increased in the active acromegaly patients and a threshold value in determining active disease was defined for serum matrix metalloproteinase-2 level. This study is the first to compare acromegaly patients having active or controlled disease in terms of matrix metalloproteinase-2 and matrix metalloproteinase-9 levels. The results need to be confirmed by a study that will be conducted in a larger patient group also including a healthy control group to demonstrate the value of this novel marker in disease activity.
Literature
1.
go back to reference S. Melmed, Medical progress: acromegaly. N. Eng. J. Med. 355, 2558–2573 (2006)CrossRef S. Melmed, Medical progress: acromegaly. N. Eng. J. Med. 355, 2558–2573 (2006)CrossRef
2.
go back to reference S. Melmed, A. Colao, A. Barkan, M. Molitch, A.B. Grossman, D. Klienberg, D. Clemmons, P. Chanson, E. Laws, J. Schlechte, M.L. Vance, K. Ho, A. Giustina; Acromegaly Consensus Group., guidelines for acromegaly management: an update. J. Clin. Endocrinol. Metab. 94, 1509–1517 (2009)CrossRef S. Melmed, A. Colao, A. Barkan, M. Molitch, A.B. Grossman, D. Klienberg, D. Clemmons, P. Chanson, E. Laws, J. Schlechte, M.L. Vance, K. Ho, A. Giustina; Acromegaly Consensus Group., guidelines for acromegaly management: an update. J. Clin. Endocrinol. Metab. 94, 1509–1517 (2009)CrossRef
3.
go back to reference E.O. Machado, G.F. Taboada, L.V. Neto, F.R. van Haute, L.L. Corrêa, G.A. Balarini, Y. Shrank, M. Goulart, M.R. Gadelha, Prevalence of discordant GH and IGF-I levels in acromegalics at diagnosis, after surgical treatment and during treatment with octreotide LAR. Growth. Horm. IGF Res. 18, 389–393 (2008)CrossRef E.O. Machado, G.F. Taboada, L.V. Neto, F.R. van Haute, L.L. Corrêa, G.A. Balarini, Y. Shrank, M. Goulart, M.R. Gadelha, Prevalence of discordant GH and IGF-I levels in acromegalics at diagnosis, after surgical treatment and during treatment with octreotide LAR. Growth. Horm. IGF Res. 18, 389–393 (2008)CrossRef
4.
go back to reference I.M. Holdaway, M.J. Bolland, G.D. Gamble, A meta-analysis of the effect of lowering serum levels of GH and IGF-I on mortality in acromegaly. Eur. J. Endocrinol 159, 89–95 (2008)CrossRef I.M. Holdaway, M.J. Bolland, G.D. Gamble, A meta-analysis of the effect of lowering serum levels of GH and IGF-I on mortality in acromegaly. Eur. J. Endocrinol 159, 89–95 (2008)CrossRef
5.
go back to reference M.R. Farnoud, F. Farhadian, J.L. Samuel, P. Derome, F. Peillon, J.Y. Li, Fibronectin isoforms are differentially expressed in normal and adenomatous human anterior pituitaries. Int. J. Cancer 61, 27–34 (1995)CrossRef M.R. Farnoud, F. Farhadian, J.L. Samuel, P. Derome, F. Peillon, J.Y. Li, Fibronectin isoforms are differentially expressed in normal and adenomatous human anterior pituitaries. Int. J. Cancer 61, 27–34 (1995)CrossRef
6.
go back to reference K. Thapar, K. Kovacs, B.W. Scheithauer, L. Stefaneanu, E. Horvath, P.J. Pernicone, D. Murray, E.R. Laws Jr., Proliferative activity and invasiveness among pituitary adenomas and carcinomas: an analysis using the MIB-1 antibody. Neurosurgery 38, 99–106 (1996)CrossRef K. Thapar, K. Kovacs, B.W. Scheithauer, L. Stefaneanu, E. Horvath, P.J. Pernicone, D. Murray, E.R. Laws Jr., Proliferative activity and invasiveness among pituitary adenomas and carcinomas: an analysis using the MIB-1 antibody. Neurosurgery 38, 99–106 (1996)CrossRef
7.
go back to reference A. Page-McCaw, A.J. Ewald, Z. Werb, Matrix metalloproteinases and the regulation of tissue remodelling. Nat. Rev. Mol. Cell Biol. 8, 221–233 (2007)CrossRef A. Page-McCaw, A.J. Ewald, Z. Werb, Matrix metalloproteinases and the regulation of tissue remodelling. Nat. Rev. Mol. Cell Biol. 8, 221–233 (2007)CrossRef
8.
go back to reference A. Nagase, R. Visse, G. Murphy, Structure and function of matrix metalloproteinases and TIMPs. Cardiovasc. Res. 69, 562–573 (2006)CrossRef A. Nagase, R. Visse, G. Murphy, Structure and function of matrix metalloproteinases and TIMPs. Cardiovasc. Res. 69, 562–573 (2006)CrossRef
9.
go back to reference M.J. Duff, The role of proteolytic enzymes in cancer invasion and metastasis. Clin. Exp. Metastasis. 10, 145–155 (1992)CrossRef M.J. Duff, The role of proteolytic enzymes in cancer invasion and metastasis. Clin. Exp. Metastasis. 10, 145–155 (1992)CrossRef
10.
go back to reference H. Kawamoto, T. Uozomi, K. Kawamoto, K. Arita, Y. Yano, T. Hirohata, Type IV collagenase activity and cavernous sinus invasion in human pituitary adenomas. Acta Neurochir. (Wien). 138, 390–395 (1996)CrossRef H. Kawamoto, T. Uozomi, K. Kawamoto, K. Arita, Y. Yano, T. Hirohata, Type IV collagenase activity and cavernous sinus invasion in human pituitary adenomas. Acta Neurochir. (Wien). 138, 390–395 (1996)CrossRef
11.
go back to reference W. Liu, Y. Matsumoto, M. Okada, K. Miyake, K. Kunishio, N. Kawai, T. Tamiya, S. Nagao, Matrix metalloproteinase 2 and 9 expression correlated with cavernous sinus invasion of pituitary adenomas. J. Med. Invest. 52, 151–158 (2005)CrossRef W. Liu, Y. Matsumoto, M. Okada, K. Miyake, K. Kunishio, N. Kawai, T. Tamiya, S. Nagao, Matrix metalloproteinase 2 and 9 expression correlated with cavernous sinus invasion of pituitary adenomas. J. Med. Invest. 52, 151–158 (2005)CrossRef
12.
go back to reference E. Beaulieu, Z. Kachra, N. Mousseau, L. Delbecchi, J. Hardy, R. Béliveau, Matrix metalloproteinases and their inhibitors in human pituitary tumors. Neurosurgery 45, 1432–1440 (1999)CrossRef E. Beaulieu, Z. Kachra, N. Mousseau, L. Delbecchi, J. Hardy, R. Béliveau, Matrix metalloproteinases and their inhibitors in human pituitary tumors. Neurosurgery 45, 1432–1440 (1999)CrossRef
13.
go back to reference S. Yokoyama, H. Hirano, K. Moraki, M. Goto, S. Imamura, J.I. Kuratsu, Are nonfunctioning pituitary adenomas extending into the cavernous sinus aggressive and/or invasive? Neurosurgery 49, 857–862 (2001)PubMed S. Yokoyama, H. Hirano, K. Moraki, M. Goto, S. Imamura, J.I. Kuratsu, Are nonfunctioning pituitary adenomas extending into the cavernous sinus aggressive and/or invasive? Neurosurgery 49, 857–862 (2001)PubMed
14.
go back to reference U.J. Knappe, C. Hagel, B.W. Lisboa, W. Wilczak, D.K. Lüdecke, W. Saeger, Expression of serine proteases and metalloproteinases in human pituitary adenomas and anterior pituitary lobe tissue. Acta Neuropathol. 106, 471–478 (2003)CrossRef U.J. Knappe, C. Hagel, B.W. Lisboa, W. Wilczak, D.K. Lüdecke, W. Saeger, Expression of serine proteases and metalloproteinases in human pituitary adenomas and anterior pituitary lobe tissue. Acta Neuropathol. 106, 471–478 (2003)CrossRef
15.
go back to reference M. Páez Pereda, M.F. Ledda, V. Goldberg, A. Chervín, G. Carrizo, H. Molina, A. Müller, U. Renner, O. Podhajcer, E. Arzt, G.K. Stalla, High levels of matrix metalloproteinases regulate proliferation and hormone secretion in pituitary cells. J. Clin. Endocrinol. Metab. 85, 263–269 (2000)PubMed M. Páez Pereda, M.F. Ledda, V. Goldberg, A. Chervín, G. Carrizo, H. Molina, A. Müller, U. Renner, O. Podhajcer, E. Arzt, G.K. Stalla, High levels of matrix metalloproteinases regulate proliferation and hormone secretion in pituitary cells. J. Clin. Endocrinol. Metab. 85, 263–269 (2000)PubMed
16.
go back to reference J. Daroszewski, M. Bolanowski, M. Kaluzny, M. Siewinski, The imbalance of cathepsin B-like activity in acromegalic patients-preliminary report. Neuro. Endocrinol. Lett. 31, 256–260 (2010)PubMed J. Daroszewski, M. Bolanowski, M. Kaluzny, M. Siewinski, The imbalance of cathepsin B-like activity in acromegalic patients-preliminary report. Neuro. Endocrinol. Lett. 31, 256–260 (2010)PubMed
17.
go back to reference A. Giustina, P. Chanson, M.D. Bronstein, A. Klibanski, S. Lamberts, F.F. Casanueva, P. Trainer, E. Ghigo, K. Ho, S. Melmed; Acromegaly Consensus Group., A consensus on criteria for cure of acromegaly. J. Clin. Endocrinol. Metab. 95, 3141–3148 (2010)CrossRef A. Giustina, P. Chanson, M.D. Bronstein, A. Klibanski, S. Lamberts, F.F. Casanueva, P. Trainer, E. Ghigo, K. Ho, S. Melmed; Acromegaly Consensus Group., A consensus on criteria for cure of acromegaly. J. Clin. Endocrinol. Metab. 95, 3141–3148 (2010)CrossRef
18.
go back to reference K. Yoshimura, T. Tsuchida, K. Kawamoto, Expression of cathepsin B and cystatin C in the human adenohypophysis and in pituitary adenomas. Oncol. Rep. 7, 27–31 (2000)PubMed K. Yoshimura, T. Tsuchida, K. Kawamoto, Expression of cathepsin B and cystatin C in the human adenohypophysis and in pituitary adenomas. Oncol. Rep. 7, 27–31 (2000)PubMed
19.
go back to reference I. Berdowska, Cysteine proteases as disease markers. Clin. Chim. Acta 342, 41–69 (2004)CrossRef I. Berdowska, Cysteine proteases as disease markers. Clin. Chim. Acta 342, 41–69 (2004)CrossRef
20.
go back to reference A.N. Paisley, C.J. O’Callaghan, K.C. Lewandowski, C. Parkinson, M.E. Roberts, W.M. Drake, J.P. Monson, P.J. Trainer, H.S. Randeva, Reductions of circulating matrix metalloproteinase 2 and vascular endothelial growth factor levels after treatment with pegvisomant in subjects with acromegaly. J. Clin. Endocrinol. Metab. 91, 4635–4640 (2006)CrossRef A.N. Paisley, C.J. O’Callaghan, K.C. Lewandowski, C. Parkinson, M.E. Roberts, W.M. Drake, J.P. Monson, P.J. Trainer, H.S. Randeva, Reductions of circulating matrix metalloproteinase 2 and vascular endothelial growth factor levels after treatment with pegvisomant in subjects with acromegaly. J. Clin. Endocrinol. Metab. 91, 4635–4640 (2006)CrossRef
21.
go back to reference G.A. Kanakis, A. Chrisoulidou, A. Bargiota, L. Efstathiadou, A. Papanastasiou, A. Theodoropoulou, S.K. Tigas, D.A. Vassiliadi, S. Tsagarakis, M. Alevizaki, The ongoing challenge of discrepant growth hormone and insulin-like growth factor I results in the evaluation of treated acromegalic patients: a systematic review and meta analysis. Clin. Endocrinol. (Oxf). 85, 681–688 (2016)CrossRef G.A. Kanakis, A. Chrisoulidou, A. Bargiota, L. Efstathiadou, A. Papanastasiou, A. Theodoropoulou, S.K. Tigas, D.A. Vassiliadi, S. Tsagarakis, M. Alevizaki, The ongoing challenge of discrepant growth hormone and insulin-like growth factor I results in the evaluation of treated acromegalic patients: a systematic review and meta analysis. Clin. Endocrinol. (Oxf). 85, 681–688 (2016)CrossRef
22.
go back to reference E.T. Cerit, K. Ağbaht, Ö. Demir, M. Şahin, V.T. Gedik, C. Özcan, D. Çorapçıoğlu, Discordance between GH and IGF-1 levels in Turkish acromegalic patients. Endocr. Pract. 22, 1422–1428 (2016)CrossRef E.T. Cerit, K. Ağbaht, Ö. Demir, M. Şahin, V.T. Gedik, C. Özcan, D. Çorapçıoğlu, Discordance between GH and IGF-1 levels in Turkish acromegalic patients. Endocr. Pract. 22, 1422–1428 (2016)CrossRef
23.
go back to reference P.U. Freda, Monitoring of acromegaly: what should be performed when GH and IGF-1 levels are discrepant? Clin. Endocrinol. (Oxf). 71, 166–170 (2009)CrossRef P.U. Freda, Monitoring of acromegaly: what should be performed when GH and IGF-1 levels are discrepant? Clin. Endocrinol. (Oxf). 71, 166–170 (2009)CrossRef
24.
go back to reference H.J. Kim, S.H. Kwon, S.W. Kim, D.J. Park, C.S. Shin, K.S. Park, S.Y. Kim, B.Y. Cho, H.K. Lee, Diagnostic value of serum IGF-I and IGFBP-3 in growth hormone disorders in adults. Horm. Res. 56, 117–123 (2001)PubMed H.J. Kim, S.H. Kwon, S.W. Kim, D.J. Park, C.S. Shin, K.S. Park, S.Y. Kim, B.Y. Cho, H.K. Lee, Diagnostic value of serum IGF-I and IGFBP-3 in growth hormone disorders in adults. Horm. Res. 56, 117–123 (2001)PubMed
25.
go back to reference M. Arosio, S. Garrone, P. Bruzzi, G. Faglia, F. Minuto, A. Barreca, Diagnostic value of the acid-labile subunit in acromegaly: evaluation in comparison with insulin-like growth factor (IGF) I, and IGF-binding protein 1, -2, -3. J. Clin. Endocrinol. Metab. 86, 1091–1098 (2001)PubMed M. Arosio, S. Garrone, P. Bruzzi, G. Faglia, F. Minuto, A. Barreca, Diagnostic value of the acid-labile subunit in acromegaly: evaluation in comparison with insulin-like growth factor (IGF) I, and IGF-binding protein 1, -2, -3. J. Clin. Endocrinol. Metab. 86, 1091–1098 (2001)PubMed
Metadata
Title
Matrix metalloproteinase 2 (MMP-2) levels are increased in active acromegaly patients
Authors
Alper Cagri Karci
Zeynep Canturk
Ilhan Tarkun
Berrin Cetinarslan
Publication date
01-07-2017
Publisher
Springer US
Published in
Endocrine / Issue 1/2017
Print ISSN: 1355-008X
Electronic ISSN: 1559-0100
DOI
https://doi.org/10.1007/s12020-017-1283-8

Other articles of this Issue 1/2017

Endocrine 1/2017 Go to the issue